Trials / Terminated
TerminatedNCT03649321
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
A phase1b/2 Clinical Trial of Chemotherapy and the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Determine the overall response rate (ORR) of bemcentinib plus chemotherapy (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.
Detailed description
Bemcentinib inhibits pancreatic cancer proliferation as monotherapy and in combination with gemcitabine through inhibition of the Axl pathway. The combination of nab-paclitaxel/gemcitabine has encouraging signs of clinical activity in patients with metastatic pancreatic cancer38. We would like to build on this combination in a biomarker driven phase 1b/2 clinical trial of bemcentinib in nab-paclitaxel/gemcitabine for patients with metastatic pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bemcentinib | 200mg orally starting Cycle 1 day 2 every 21 days or 28 days. |
| DRUG | Nab-paclitaxel | 25 mg/m\^2 Day 1 /8 every 21 days or 28 days. |
| DRUG | Gemcitabine | Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days |
| DRUG | Cisplatin | Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days |
Timeline
- Start date
- 2019-01-03
- Primary completion
- 2022-06-27
- Completion
- 2022-06-27
- First posted
- 2018-08-28
- Last updated
- 2023-11-09
- Results posted
- 2023-11-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03649321. Inclusion in this directory is not an endorsement.